CERo Therapeutics Holdings (CERo Therapeutics Holdings) Total Liabilities : $46.22 Mil (As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Total Liabilities?

CERo Therapeutics Holdings's Total Liabilities for the quarter that ended in Dec. 2022 was $46.22 Mil.

CERo Therapeutics Holdings's quarterly Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2021 ($47.60 Mil) but then declined from Dec. 2021 ($47.60 Mil) to Dec. 2022 ($46.22 Mil).

CERo Therapeutics Holdings's annual Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2021 ($47.60 Mil) but then declined from Dec. 2021 ($47.60 Mil) to Dec. 2022 ($46.22 Mil).

CERo Therapeutics Holdings Total Liabilities Historical Data

The historical data trend for CERo Therapeutics Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Total Liabilities Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Total Liabilities

47.60

46.22

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Total Liabilities	47.60	46.22

CERo Therapeutics Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CERo Therapeutics Holdings's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.164	+	(2.345	+	42.711
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	46.22

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	11.349	-	-34.871
	=	46.22

CERo Therapeutics Holdings's Total Liabilities for the quarter that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.164	+	(2.345	+	42.711
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	46.22

Total Liabilities	=	Total Assets (Q: Dec. 2022 )	-	Total Equity (Q: Dec. 2022 )
	=	11.349	-	-34.871
	=	46.22

CERo Therapeutics Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024